The FDA has recently approved Xiidra (lifitegrast; Shire) to treat the signs and symptoms of dry eye disease in adults. Drs. Andy Morgenstern and Walt Whitley discuss how this new drug should fit into an optometrist’s treatment strategy. Andy says that since not every patient responds the same way to treatment, having an alternative is beneficial. Walt suggests that some physicians will likely take a “wait and see” approach to evaluate the medication. He says, however, that having a new option to treat dry eye disease ultimately benefits patients.